Low-cost diagnostic test for susceptible and drug-resistant tuberculosis in rural Malawi

African Journal of Laboratory Medicine

 
 
Field Value
 
Title Low-cost diagnostic test for susceptible and drug-resistant tuberculosis in rural Malawi
 
Creator Zhang, Annie Jumbe, Enoch Krysiak, Robert Sidiki, Sabeen Kelley, Holden V. Chemey, Elly K. Kamba, Chancy Mwapasa, Victor García, Juan I. Norris, Alison Pan, Xueliang J. Evans, Carlton Wang, Shu-Hua Kwiek, Jesse J. Torrelles, Jordi B.
 
Subject Medicine; Infectious Diseases; Diagnostics Tuberculosis; Mycobacterium tuberculosis;Diagnosis; Drug resistance
Description Background: Rural settings where molecular tuberculosis diagnostics are not currently available need easy-to-use tests that do not require additional processing or equipment. While acid-fast bacilli (AFB) smear is the most common and often only tuberculosis diagnosis test performed in rural settings, it is labour intensive, has less-than-ideal sensitivity, and cannot assess tuberculosis drug susceptibility patterns. Objective: The objective of this study was to determine the feasibility of a multidrug-resistant (MDR) or extensively drug-resistant (XDR)-tuberculosis coloured agar-based culture test (tuberculosis CX-test), which can detect Mycobacterium tuberculosis growth and evaluate for drug susceptibility to isoniazid, rifampicin and a fluoroquinolone (i.e. ciprofloxacin) in approximately 14 days. Method: In this study, 101 participants were enrolled who presented to a rural health clinic in central Malawi. They were suspected of having active pulmonary tuberculosis. Participants provided demographic and clinical data and submitted sputum samples for tuberculosis testing using the AFB smear and tuberculosis CX-test. Results: The results showed a high level of concordance between the AFB smear (12 positive) and tuberculosis CX-test (13 positive); only one sample presented discordant results, with the molecular GeneXpert MTB/RIF® test confirming the tuberculosis CX-test results. The average time to a positive tuberculosis CX-test was 10 days. Of the positive samples, the tuberculosis CX-test detected no cases of drug resistance, which was later confirmed by the GeneXpert MTB/RIF®. Conclusion: These findings demonstrate that the tuberculosis CX-test could be a reliable low-cost diagnostic method for active pulmonary tuberculosis in high tuberculosis burden rural areas.
 
Publisher AOSIS
 
Contributor The Ohio State University Public Health Preparedness for Infectious Diseases/Office of International Affairs
Date 2018-06-04
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Field Study
Format text/html application/epub+zip application/xml application/pdf
Identifier 10.4102/ajlm.v7i1.690
 
Source African Journal of Laboratory Medicine; Vol 7, No 1 (2018); 6 pages 2225-2010 2225-2002
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://ajlmonline.org/index.php/ajlm/article/view/690/1008 https://ajlmonline.org/index.php/ajlm/article/view/690/1007 https://ajlmonline.org/index.php/ajlm/article/view/690/1009 https://ajlmonline.org/index.php/ajlm/article/view/690/1002
 
Coverage Malawi — —
Rights Copyright (c) 2018 Annie Zhang, Enoch Jumbe, Robert Krysiak, Sabeen Sidiki, Holden V Kelley, Elly K. Chemey, Chancy Kamba, Victor Mwapasa, Juan I. García, Alison Norris, Xueliang (Jeff) Pan, Carlton Evans, Shu-Hua Wang, Jesse Kwiek, Jordi B Torrelles https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT